US2022331367A1PendingUtilityA1

Pharmaceutical composition for use in improving quality of scalp or skin, wound healing, or improving quality of hair

68
Assignee: Fukuoka HirotaroPriority: Oct 2, 2017Filed: Jul 1, 2022Published: Oct 20, 2022
Est. expiryOct 2, 2037(~11.2 yrs left)· nominal 20-yr term from priority
Inventors:Hirotaro Fukuoka
A61Q 7/00A61P 17/02A61K 9/0019A61K 38/00A61P 17/14A61Q 5/12A61K 9/0014A61Q 19/08A61P 17/00A61K 9/08A61K 8/64A61K 35/28A61K 8/98A61K 9/0021C12N 2500/02C12N 5/0667
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a pharmaceutical composition for use in modifying scalp or skin, promoting wound healing, or modifying hair, comprising a secretion from adipose stem cells as an active ingredient, wherein 0.3 to 0.6 μg of the secretion in terms of protein abundance per site in scalp or skin is administered.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for topical administration, for use in modifying scalp or skin, comprising a secretion from adipose stem cells as an active ingredient, wherein 0.3 to 0.6 μg of the secretion is administered in terms of protein abundance per site in scalp or skin. 
     
     
         2 . A pharmaceutical composition for topical administration, for use in treating a wound, comprising a secretion from adipose stem cells as an active ingredient, wherein 0.3 to 0.6 μg of the secretion is administered in terms of protein abundance per site in wound. 
     
     
         3 . A pharmaceutical composition for topical administration for use in modifying hair, comprising a secretion from adipose stem cells as an active ingredient, wherein 0.3 to 0.6 μg of the secretion is administered in terms of protein abundance per site in scalp or skin. 
     
     
         4 . The pharmaceutical composition according to  claim 3 , wherein the hair modification is reduction of gray hair. 
     
     
         5 . The pharmaceutical composition according to  claim 3 , wherein the hair modification is amelioration of roughness of hair cuticles. 
     
     
         6 . The pharmaceutical composition according to  claim 3 , wherein the hair modification is amelioration of hair thickness or growth rate. 
     
     
         7 . The pharmaceutical composition according to  claim 1 , which is administered at a rate of 1 site per 1 cm 2  to 4 cm 2  of a surface of scalp or skin. 
     
     
         8 . The pharmaceutical composition according to  claim 1 , which is administered in a solution volume of 10 to 30 μL per site. 
     
     
         9 . The pharmaceutical composition according to  claim 1 , wherein the administration interval is from twice a month to once every 6 months.

Join the waitlist — get patent alerts

Track US2022331367A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.